| Sorafenib in advanced hepatocellular carcinoma JM Llovet, S Ricci, V Mazzaferro, P Hilgard, E Gane, JF Blanc, ... New England journal of medicine 359 (4), 378-390, 2008 | 14871 | 2008 |
| FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer T Conroy, F Desseigne, M Ychou, O Bouché, R Guimbaud, Y Bécouarn, ... New England journal of medicine 364 (19), 1817-1825, 2011 | 7927 | 2011 |
| EASL clinical practice guidelines: management of hepatocellular carcinoma PR Galle, A Forner, JM Llovet, V Mazzaferro, F Piscaglia, JL Raoul, ... Journal of hepatology 69 (1), 182-236, 2018 | 6185 | 2018 |
| Sunitinib malate for the treatment of pancreatic neuroendocrine tumors E Raymond, L Dahan, JL Raoul, YJ Bang, I Borbath, C Lombard-Bohas, ... New England Journal of Medicine 364 (6), 501-513, 2011 | 2935 | 2011 |
| FOLFIRINOX or gemcitabine as adjuvant therapy for pancreatic cancer T Conroy, P Hammel, M Hebbar, M Ben Abdelghani, AC Wei, JL Raoul, ... New England Journal of Medicine 379 (25), 2395-2406, 2018 | 2405 | 2018 |
| Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open … A Wang-Gillam, CP Li, G Bodoky, A Dean, YS Shan, G Jameson, ... The Lancet 387 (10018), 545-557, 2016 | 1155 | 2016 |
| Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial J Bruix, JL Raoul, M Sherman, V Mazzaferro, L Bolondi, A Craxi, PR Galle, ... Journal of hepatology 57 (4), 821-829, 2012 | 928 | 2012 |
| Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: results from the randomized phase III BRISK-FL study PJ Johnson, S Qin, JW Park, RTP Poon, JL Raoul, PA Philip, CH Hsu, ... Journal of clinical oncology 31 (28), 3517-3524, 2013 | 830 | 2013 |
| Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma … V Vilgrain, H Pereira, E Assenat, B Guiu, AD Ilonca, GP Pageaux, A Sibert, ... The Lancet Oncology 18 (12), 1624-1636, 2017 | 770 | 2017 |
| Heterogeneity of patients with intermediate (BCLC B) Hepatocellular Carcinoma: proposal for a subclassification to facilitate treatment decisions L Bolondi, A Burroughs, JF Dufour, PR Galle, V Mazzaferro, F Piscaglia, ... Seminars in liver disease 32 (04), 348-359, 2012 | 715 | 2012 |
| Evolving strategies for the management of intermediate-stage hepatocellular carcinoma: available evidence and expert opinion on the use of transarterial chemoembolization JL Raoul, B Sangro, A Forner, V Mazzaferro, F Piscaglia, L Bolondi, ... Cancer treatment reviews 37 (3), 212-220, 2011 | 657 | 2011 |
| Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: results from the randomized phase III BRISK-PS study JM Llovet, T Decaens, JL Raoul, E Boucher, M Kudo, C Chang, YK Kang, ... Journal of Clinical Oncology 31 (28), 3509-3516, 2013 | 651 | 2013 |
| Impact of FOLFIRINOX compared with gemcitabine on quality of life in patients with metastatic pancreatic cancer: results from the PRODIGE 4/ACCORD 11 randomized trial S Gourgou-Bourgade, C Bascoul-Mollevi, F Desseigne, M Ychou, ... J Clin Oncol 31 (1), 23-29, 2013 | 529 | 2013 |
| Treatment of intermediate-stage hepatocellular carcinoma A Forner, M Gilabert, J Bruix, JL Raoul Nature reviews Clinical oncology 11 (9), 525-535, 2014 | 516 | 2014 |
| Updated use of TACE for hepatocellular carcinoma treatment: How and when to use it based on clinical evidence JL Raoul, A Forner, L Bolondi, TT Cheung, R Kloeckner, T de Baere Cancer treatment reviews 72, 28-36, 2019 | 464 | 2019 |
| Definitive chemoradiotherapy with FOLFOX versus fluorouracil and cisplatin in patients with oesophageal cancer (PRODIGE5/ACCORD17): final results of a randomised, phase 2/3 trial T Conroy, MP Galais, JL Raoul, O Bouché, S Gourgou-Bourgade, ... The lancet oncology 15 (3), 305-314, 2014 | 415 | 2014 |
| Individual fluorouracil dose adjustment based on pharmacokinetic follow-up compared with conventional dosage: results of a multicenter randomized trial of patients with … E Gamelin, R Delva, J Jacob, Y Merrouche, JL Raoul, D Pezet, E Dorval, ... Journal of clinical oncology 26 (13), 2099-2105, 2008 | 413 | 2008 |
| Phase II trial of oxaliplatin as first-line chemotherapy in metastatic colorectal cancer patients. Digestive Group of French Federation of Cancer Centers. Y Becouarn, M Ychou, M Ducreux, C Borel, F Bertheault-Cvitkovic, ... Journal of Clinical Oncology 16 (8), 2739-2744, 1998 | 372 | 1998 |
| Prospective randomized trial of chemoembolization versus intra‐arterial injection of 131I‐labeled–iodized oil in the treatment of hepatocellular carcinoma J Raoul, D Guyader, J Bretagne, J Heautot, R Duvauferrier, P Bourguet, ... Hepatology 26 (5), 1156-1161, 1997 | 363 | 1997 |
| Comparison of tumor response by Response Evaluation Criteria in Solid Tumors (RECIST) and modified RECIST in patients treated with sorafenib for hepatocellular carcinoma J Edeline, E Boucher, Y Rolland, E Vauléon, M Pracht, C Perrin, ... Cancer 118 (1), 147-156, 2012 | 356 | 2012 |
